There was good news and bad news for Zynerba Pharmaceuticals (NASDAQ:ZYNE) in 2017. First, the good news: The cannabinoid-focused biotech stock is up more than 90% over the last three months. What’s the bad news? That gain wasn’t enough to offset Zynerba’s previous decline. The stock is … Read More
The post Can This Beaten-Down Marijuana Stock Roar Back in 2018? appeared first on Dagga Magazine.